AAPG - Ascentage Pharma Group International Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

NASDAQ

$18.28

▼ DOWN 2.42% (-0.45)

KEY STATISTICS

Market Cap$1.70 B

52w High$42.47

52w Low$16.36

Dividend Yield—

Frequency—

P/E-9.37

Volume6.25K

Shares Out.92.96M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Dajun Yang

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 24, 2025

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

767

PRICE TARGET

Target High$40.00

Target Low$40.00

Target Median$40.00

Target Consensus$40.00

UPCOMING EARNINGS

DateMar 31, 2027

DayWednesday

Rev. Est.$48.61M

MAR

WED

PRICE

$18.28 ▼ DOWN 2.42% (−$0.45)

About Ascentage Pharma Group International

https://www.ascentage.com ↗

Ascentage Pharma, founded in 2009 in Suzhou, China, is a clinical-stage biotech developing therapies for cancers, HBV, and age-related diseases, with a diverse pipeline including BCR-ABL, Bcl-2, MDM2, and kinase inhibitors.

INDUSTRY

Biotechnology

A PRODUCT ASCENTAGE PHARMA GROUP INTERNATIONAL IS KNOWN FOR

Olverembatinib (HQP1351)

Olverembatinib, Ascentage Pharma’s first approved oral third-generation BCR-ABL TKI, treats drug-resistant CML in China and is advancing global trials to expand its indications.